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Background:  The  management  of  Eisenmenger  syndrome  (ES) has dramatically  changed  since the  advent
of disease-targeted  therapy  (DTT).  However,  guidelines  for  ES  management,  including  DTT,  have  not
been  established.  We  aimed  to clarify  the  current  incidence,  underlying  disease,  and  management  of ES
in  Japan,  using  a  nationwide  survey.
Methods:  A written  questionnaire  was  sent  to members  of  the  Japanese  Society  for  Adult  Congenital  Heart
Disease,  through  which  information  was  obtained  from  86 institutions.
Results:  A  total  of 251  patients  with  ES  (80.5%  cases  ≥  20  years  of  age)  were  followed  as  of  February  2012;
DTT was  performed  in 124  (49.4%)  patients.  Unrepaired  simple  anatomy  was  reported  as  an  underlying
condition  in 165  patients  (65.7%).  Among  patients  with  ES,  55  (21.9%),  128  (51%),  53 (21.1%),  and  12
(4.8%)  were  classiﬁed  into  functional  classes  I, II, III, and  IV,  respectively.  DTT  was  routinely  performed
at  52  (60.5%)  institutions,  but there  were  variations  in the  DTT  therapeutic  strategy  at these  institu-
tions.  Combined  therapy  was  more  often  used  than  monotherapy;  an  endothelin  receptor  antagonist  was
the most  frequently  prescribed  medication.  There  were  institutional  differences  regarding  heart  failure
treatment  and  indications  for anticoagulation.  Digitalis  and  angiotensin-converting  enzyme  inhibitors  or
angiotensin  II receptor  blockers  were  widely  used,  but beta-blockers  were  infrequently  used  to manage
heart  failure.
Conclusions:  This  survey  describes  the current  status,  including  prevalence  and  underlying  disease,  and
variations  in the  practical  management  of  ES in  Japan.  The  results  will help  in  the creation  of  future
ment
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Since the advent of pediatric cardiology and cardiac surgery, the
utcomes for patients with congenital heart disease (CHD) have
igniﬁcantly improved. Consequently, the majority of patients sur-
ive to adulthood [1]. However, some of these patients continue to
xperience several long-term complications, including pulmonary
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arterial hypertension (PAH), which is reported in approximately
10% of patients with CHD [2,3]. Eisenmenger syndrome (ES) is
deﬁned as the presence of signiﬁcant PAH in conjunction with CHD
and shunt reversal [4]. Compared to idiopathic PAH, patients with
ES have better survival prospects [5]; however, the associated mor-
bidity and mortality remain high [6,7].
Recently, the therapeutic strategies for PAH have drastically
changed due to the advances of disease-targeted therapy (DTT)
involving pulmonary vasodilators, including prostanoids, endothe-
lin receptor antagonists (ERAs), and phosphodiesterase-5 (PDE-5)
inhibitors [8–11]. Over the past few years, several studies have
shown that DTT is well tolerated and improves clinical out-
comes, even in ES patients [12–15]. However, guidelines for the
vier Ltd. All rights reserved.
f Cardiology 63 (2014) 286–290 287
m
l
t
t
c
r
w
m
T
g
M
E
i
S
a
t
1
2
p
c
t
(
n
p
w
t
m
t
R
t
i
c
Table 1
Patient characteristics.
Total patients, no. 251
Adult, no. (%) 202 (80.5)
Cardiac defects, no. (%)
Unrepaired
Simple anatomy 165 (65.7)
Complex anatomy 57 (22.7)
Repaired
Simple anatomy 13 (5.2)
Complex anatomy 14 (5.6)
NYHA functional class, no. (%)
I 55 (21.9)
II  128 (51.0)
III  53 (21.1)
IV  12 (4.8)
Unclear 3 (1.2)
or mechanical valve implantation.
Table 2
Causes of death in patients with Eisenmenger syndrome.
Total patients, no. 86
Unknown causes 28
Identiﬁed causes 58
Sudden death, no. (%) 23
Unclear 13 (22.4)
Intrapulmonary hemorrhage 7 (12.1)
Arrhythmia 3 (5.2)
Non-sudden death, no. (%) 35
Heart failure 21 (36.2)
Pneumonia 6 (10.3)T. Inohara et al. / Journal o
anagement of ES, including with DTT, have not been estab-
ished because of insufﬁcient evidence. As a result, the current
herapeutic strategies for ES may  vary considerably among institu-
ions. In addition, the data in previous reports have been primarily
ollected from specialized institutions and, therefore, do not accu-
ately reﬂect the broader clinical situation. In the present study,
e aimed to assess both the underlying diseases and the manage-
ent in patients with ES through a nationwide survey in Japan.
he results of this survey will help in the development of future
uidelines for ES management.
ethods
A written questionnaire, designed to deﬁne the prevalence of
S and the current clinical management strategies, was sent to 175
nstitutions (187 departments) to which members of the Japanese
ociety for Adult Congenital Heart Disease belong. The results were
nalyzed centrally at St. Luke’s International Hospital, Tokyo, Japan.
The questionnaire was designed to record the required informa-
ion by collecting answers to questions pertaining to the following:
. Prevalence and characteristics
(A) The total numbers of patients with ES who were alive and
followed as of February 2012.
i. The numbers of adult patients.
ii. Types of CHD (simple or complex anatomy [16]).
iii. New York Heart Association (NYHA) functional class of
each patient.
iv. The numbers of patients who received DTT.
(B) The total numbers of deaths in patients with ES from April
2000 to February 2012.
i. The numbers of sudden deaths, with a description of the
details, if possible.
ii. The numbers of non-sudden deaths, with a description of
the details, if possible.
. Management
(A) Whether or not DTT was performed.
i. DTT regimen; monotherapy or combined therapy, drug
choice (multiple answers allowed).
(B) Whether or not the following drugs were prescribed to treat
heart failure: digoxin, diuretics, angiotensin-converting
enzyme inhibitors (ACE-Is) or angiotensin II receptor block-
ers (ARBs), and beta-blockers.
(C) Describe conditions under which anticoagulation therapy
(warfarin) was performed.
As previously described [4], ES was deﬁned as having the
resence of PAH at the systemic level and high pulmonary vas-
ular resistance (>10 units), with reversed or bidirectional shunts
hrough a large unrestrictive atrial or ventricular septal defect
VSD), or aorto-pulmonary communication. If catheterization was
ot performed, patients who had systemic-level pulmonary artery
ressure, estimated by echocardiography, were also included. Data
ere expressed as the number of speciﬁc responses divided by the
otal numbers of responses (%). If a question was returned with
ultiple answers, the number of speciﬁc responses was  divided by
he number of individuals who answered the question (%).
esultsOf the 175 institutions (187 departments) that received ques-
ionnaires, responses were received from 86 institutions (49.1%;
ncluding 86 departments, 46.0%). The demographic and clinical
haracteristics of the patients are described in Table 1. In total, 251NYHA, New York Heart Association.
patients with ES were followed as of February 2012. Among them,
202 patients (80.5%) were adults (aged ≥ 20 years) and the majority
(65.7%) had unrepaired simple anatomy. Approximately half of the
patients had NYHA functional class II.
From April 2000 to February 2012, a total of 86 patients with
ES died (Table 2). Although the causes were not identiﬁed in 28
individuals, 23 patients died suddenly due to intrapulmonary hem-
orrhage (n = 7), arrhythmia (n = 3), or unknown causes (n = 13). The
remaining 35 patients died due to congestive heart failure (n = 21),
pneumonia (n = 6), multiple organ failure (n = 4), cancer (n = 2),
infectious endocarditis (n = 1), or pulmonary embolism (n = 1).
There were variations in the therapeutic strategies for ES
patients (Table 3) among the various institutions. DTT was  routinely
considered in 52 institutions (60.5%), with DTT being performed
in 124 (49.4%) of the patients in this survey. Combined therapy
was more likely to be chosen than monotherapy (36 institu-
tions versus 16 institutions, respectively), and ERAs were more
frequently prescribed (45 institutions) than oral prostanoids (30
institutions) or PDE-5 inhibitors (35 institutions). Several trends
were observed regarding drug choices among the institutions.
Bosentan was preferred (44 institutions) over ambrisentan (12
institutions), and most institutions tended to use sildenaﬁl (29
institutions) as opposed to tadalaﬁl (3 institutions) to manage the
ES patients. The drugs that were used to treat heart failure included
diuretics (56 institutions, 65.1%), ACE-Is or ARBs (40 institutions,
46.5%), and beta-blockers (22 institutions, 25.6%). In more than half
of the institutions, anticoagulation therapy was performed only for
patients with a history of atrial ﬁbrillation, pulmonary embolism,Multiple organ failure 4 (6.9)
Cancer 2 (3.4)
Infectious endocarditis 1 (1.7)
Pulmonary embolism 1 (1.7)
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Table 3
Therapeutic strategy for Eisenmenger syndrome.
Total institute, no. 86
Disease-targeted therapy, no. (%)
Yes 52 (60.5)
No  18 (20.9)
No  response 16 (18.6)
Therapeutic options of disease-targeted therapy, no.
(%)
52
Monotherapy 16
Beraprost 3 (5.8)
ERA  10 (19.2)
PDE5 inhibitors 3 (5.8)
Combined therapy 36
Beraprost + ERA 4 (7.7)
Beraprost + PDE5 inhibitors 1 (1.9)
ERA  + PDE5 inhibitors 9 (17.3)
Beraprost + ERA + PDE5 inhibitors 22 (42.3)
Choice of ERA (multiple answers allowed)
Bosentan 44 (84.6)
Ambrisentan 12 (23.1)
Choice of PDE5 inhibitor (multiple answers allowed)
Sildenaﬁl 29 (55.8)
Tadalaﬁl 3 (5.8)
Therapeutic options for heart failure, no. (%) (multiple answers allowed)
Diuretics 56 (65.1)
ACE-I or ARB 40 (46.5)
Digoxin 35 (40.7)
Beta  blocker 22 (25.6)
No  response 22 (25.6)
Anticoagulation therapy
Routine use 9 (10.5)
Only for atrial ﬁbrillation, poulmonary embolism,
mechanical valve
48 (55.8)
Never use 11 (12.8)
No  response 18 (20.9)
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ﬁbbreviations:  ERA, endothelin receptor antagonist; PDE5, phosphodiesterase-5;
CE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor
locker.
iscussion
revalence and incidence
Data from the CONCOR registry – a nationwide registry of adult
atients with CHDs in the Netherlands – revealed that the preva-
ence of PAH among the 5970 registered adult patients with CHD
as 4.2%, with ES existing in 1% of the total number of registered
atients [17]. In 2007, 409,101 adult patients with CHD were esti-
ated to be alive in Japan [18]. Assuming the prevalence of ES
n the Netherlands reﬂects the Japanese situation, approximately
000 adult ES patients are believed to be alive in Japan. However,
n this study, it seems to be difﬁcult to estimate the total num-
er of patients with ES in Japan, because the cohort of this study
as collected only from institutions with cardiologists belonging
o the Japanese Society of Adult Congenital Heart Disease and was
ather limited by the small response rates. A prospective, consec-
tive, nationwide registry designed to register all cases with ES
hould be launched to estimate accurately the number of patients
ith ES.
YHA functional class
In this survey, the majority of ES patients were in NYHA func-
ional class II (51%), which is consistent with the results of a recent
tudy in Japan and Korea [19]. In a previous study, conducted in
ovember 2005, a large proportion of the patients were classi-
ed in NYHA functional class III [17]. The precise reason for theseiology 63 (2014) 286–290
reported differences in the NYHA functional class distribution of ES
patients remains unclear, and the advent of DTT may explain this
discrepancy. In 2006, Galie et al. reported a randomized, double-
blind, placebo-controlled study evaluating the effect of bosentan in
ES patients; the results indicated that bosentan was well tolerated
and improved patient exercise capacity and hemodynamics [12].
Following the publication of these results, DTT has been rapidly and
widely adopted as a therapeutic option for ES. Indeed, in this survey,
approximately half of the ES patients received DTT. Although the
comparison of NYHA functional class between patients with and
without DTT is essential to demonstrate the effects of DTT for the
improvement of NYHA grade, this study does not include questions
related to such issues.
Causes of death
This survey revealed that 86 ES patients died between April 2000
and February 2012. The prognosis of patients with ES is consid-
erably better than that of patients with idiopathic PAH [5], with
reported survival at ages 40, 50, and 60 years being 86%, 74%, and
53%, respectively [19]. Previous studies have reported that most ES
patients died from sudden cardiac death, congestive heart failure,
hemoptysis, cerebral abscesses, or thromboembolic events [20],
and that sudden death was due to a variety of causes, such as
massive intrapulmonary hemorrhage or rupture of an aneurysmal
pulmonary trunk, rather than arrhythmia [7].
In our survey, sudden deaths accounted for more than 33% of the
patient deaths, and these were mostly as a result of intrapulmonary
hemorrhage. The causes of non-sudden death were heart failure,
pneumonia, multiple organ failure, cancer, infectious endocardi-
tis, and pulmonary embolism, which are consistent with previous
reports [20]. In the present survey, deaths related to pregnancy
were not reported; however, patients with ES have an extremely
high risk of maternal complications during pregnancy and child-
birth [21].
Disease-targeted therapy
Currently, DTT is approved as the therapeutic option for patients
with ES. European Society for Cardiology (ESC) guidelines for the
diagnosis and treatment of pulmonary hypertension [16], estab-
lished in 2009, recommend the use of bosentan as a Class I
indication for WHO  functional class III patients with ES. Other ERAs,
PDE-5 inhibitors, and prostanoids are also recommended as Class
IIa indications for patients with ES.
In this survey, DTT was  more frequently performed (60.5% of
cases) than in previous studies, reﬂecting its wide and rapid adop-
tion [6,22], and combined therapy was more likely to be chosen
than monotherapy. Furthermore, among the combined therapies,
a triplet regimen including ERAs, PDE-5 inhibitors, and beraprost
were prominent in our study. Recently, Iversen et al. [23] and
D’Alto et al. [24] reported the efﬁcacy and tolerability of com-
bined sildenaﬁl and bosentan therapy. The ESC guidelines for the
diagnosis and treatment of pulmonary hypertension recommend
combined therapy for refractory cases [16], and the proportion
of cases receiving combined therapy is expected to continue to
increase as more investigations examining the use of combined
therapy for ES patients are reported.
ERAs were frequently prescribed for patients involved in this
survey, which reﬂects the amount of evidence supporting the use
of ERAs in ES patients [12,13,25–28]. BREATHE-5 was the ﬁrst ran-
domized, placebo-controlled trial in patients with ES [12], and it
demonstrated the long-term efﬁcacy and tolerability of bosentan
in an open-label extension study [13]. Ambrisentan, a selective ERA,
was prescribed at 12 institutions (23.1%) in the current survey. This
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rug was assessed for its safety and efﬁcacy in a single cohort study
n ES patients, and further investigations are required [28].
PDE-5 inhibitors comprise an alternative treatment option for
S patients, and the evidence supporting their favorable effects has
een growing [14,15,29–31]. In our survey, PDE-5 inhibitors were
rescribed at 35 institutions (60.3%), and sildenaﬁl accounted for a
ubstantial proportion of those prescriptions. There is limited evi-
ence for the effects of tadalaﬁl [14,31], and only 2 institutions
rescribed this PGE-5 inhibitor in this survey.
Previous reports have suggested that beraprost, a prostaglandin
2 analog, might also provide beneﬁcial effects during the early
hase of treatment in patients with ES [32], but also that this
avorable effect becomes attenuated over time [33]. In Western
ountries, beraprost is currently prescribed only in limited cases,
ccording to the results of previous studies, whereas up to 30 insti-
utions (57.7%) prescribed it in this survey, which may  be attributed
o its cost-effectiveness and safety.
The effectiveness of DTT for pulmonary artery hypertension has
een established [16], and this concept is endorsed for the treat-
ent for ES, which is reﬂected in this study. However, this study
oes not provide sufﬁcient data to emphasize the current concept of
TT, established for treatment of PAH, because of the study design;
herefore, further studies are needed.
eart failure treatment strategy
There have only been few randomized controlled trials of any
edications for heart failure in patients with CHD. Shaddy et al.
eported a randomized controlled trial examining the effects of
arvedilol for children and adolescents with heart failure, including
hose with CHD [34]. Their trial concluded that carvedilol did not
mprove the clinical outcomes, contradicting the results of previ-
us studies conducted in adult patients with heart failure [35–37].
owever, recently, a few reports described the beneﬁcial aspects of
eta-blockers, including carvedilol, for patients with CHD or right
entricular systemic dysfunction [38,39]. In a reﬂection of these
ackgrounds, one tenth of institutes routinely prescribed beta-
locker for heart failure treatment accompanied with CHD in this
tudy. Further investigations regarding the efﬁcacy of beta-blockers
or treating heart failure accompanied with ES are expected.
nticoagulation therapy
Although the ESC guideline has recommended oral antico-
gulant treatment for patients with PAH [24], the value of
nticoagulation in ES patients has not been established. Indeed,
S has been associated with both bleeding and clotting tendencies
7,20,40,41]. These conﬂicting observations make developing rec-
mmendations for the use of anitcoagulants in ES patients difﬁcult.
ecently, a retrospective cohort study revealed that anticoagu-
ation did not affect long-term survival in ES patients [42], and
hat the indications should be carefully considered. In our survey,
nticoagulation was performed only for selected cases at most insti-
utions. However, a small minority of institutions routinely applied
nticoagulation therapy. Such strategic variations among institu-
ions should be discussed, and the best practice should be adopted
roadly.
Recently in Japan, new anticoagulation drugs, such as dabiga-
ran, rivaroxaban, and apixaban, have been approved. However,
ecause the indication for the use of these new anticoagulants is
estricted to atrial ﬁbrillation caused by non-valvular heart disease
nd the period between the approval of dabigatran, the ﬁrst alter-
ative to warfarin, and the start of this study was short, we  did not
ocus on these new anticoagulants in this survey. Further studiesiology 63 (2014) 286–290 289
are needed to evaluate the efﬁcacy and safety of new anticoagula-
tion drugs for ES patients.
Study limitations
Our survey has several limitations. First, written questionnaires
were sent only to the institutions with cardiologists belonging to
the Japanese Society of Adult Congenital Heart Disease. In Japan,
many additional institutions provide medical care for ES patients,
and these institutions were not considered in this survey. Second,
the institutions that responded to the questionnaires are believed
to be representative of the major Japanese medical facilities that
manage adult CHD; however, there is a possibility that the level
of response introduced a positive bias into the study. Third, out-
come measures for the diagnosis and treatment of ES were not
assessed. Finally, the diagnosis of ES was  not validated, and whether
the patients whose pulmonary vascular resistance had already
improved with DTT were included as ES remains unclear in this
study; therefore, the reported incidence of ES may not reﬂect the
real number of cases.
Conclusion
This is the ﬁrst nationwide survey examining the current status
and management of ES in Japan. This survey revealed that DTT is
widely used and that there are variations in the therapeutic strate-
gies for patients with ES employed by the different institutions.
The results will help in the creation of future guidelines for ES
management.
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